PT-141 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Produced by Patrick Uden, directed by Taghi Amirani, made by Uden Associates 6 August New York! New York!, about sewage; New York makes enough sewage each day to fill the Yankee Stadium ten times, with seven million people; it had 80,000 miles of electric cable; a new sewage tunnel 60 miles long, 800 ft below ground, was being built, to be finished in the next century - the New York City Water Tunnel No. 3 is expected to be finished by 2032 13 August Fatal Attraction, about road transport; Britain subsidised rail £2 per mile, West Germany was £5 per mile; Reinhard Gutter of Cologne; traffic calming hadmainly begun in West Germany, from 1976; John Whitelegg; transport psychologist Carina van Knippenburg of the University of Gronigen; in 1987, the Dutch government introduced rationing of car transport, also trialled in Hong Kong; Ian Catling, and road pricing; Martin Paget in Birmingham; Talib Rothengatter, and the resignation of the Dutch government in April 1989; Philip Goodwin; Martin Mogridge of UCL. Narrated by Simon Ward, produced by Stewart Lansley, directed by Andy Mayer, made by Juniper Productions 20 August The Defender, building a new fighter plane in Canada; Chris Ball, of Bristol Aerospace in Winnipeg, and Bob Diemert are building a fighter plane in Carman, Manitoba; Bob Diemert flew one of his restored Hurricane XII aircraft in the 1969 Battle of Britain; the Commemorative Air Force at Harlingen, Texas; his plane attempts to take off, but it is something akin to a scene from Those Magnificent Men in Their Flying Machines.
Methane clumped isotopes are methane molecules that contain two or more rare isotopes. Methane (CH4) contains two elements, carbon and hydrogen, each of which has two stable isotopes. For carbon, 98.9% are in the form of carbon-12 (12C) and 1.1% are carbon-13 (13C); while for hydrogen, 99.99% are in the form of protium (1H) and 0.01% are deuterium (2H or D). Carbon-13 (13C) and deuterium (2H or D) are rare isotopes in methane molecules. The abundance of the clumped isotopes provides information independent from the traditional carbon or hydrogen isotope composition of methane molecules.
== History == The therapeutic efficacy of subcutaneous pegcetacoplan in treating paroxysmal nocturnal hemoglobinuria has been established through several clinical trials. Initial phase I and II trials, such as PADDOCK, PALOMINO, and PHAROAH, evaluated pegcetacoplan in participants with paroxysmal nocturnal hemoglobinuria who had not received a complement inhibitor or had previously received eculizumab. These trials demonstrated that 1–2 years of pegcetacoplan treatment effectively controlled hemolysis and improved quality of life in participants with paroxysmal nocturnal hemoglobinuria. Building upon these findings, the efficacy of pegcetacoplan was further assessed in phase III trials. The PRINCE trial, a 26-week study, focused on complement inhibitor-naïve participants with paroxysmal nocturnal hemoglobinuria, while the PEGASUS trial, a 48-week multinational study, included complement inhibitor-treated participants with paroxysmal nocturnal hemoglobinuria. In these trials, subcutaneous pegcetacoplan was administered at a dosage of 1080 mg twice weekly, delivered as a 20-mL subcutaneous infusion. Participants had the option to self-administer the medication or have it administered by qualified research personnel.
== Commercial and clinical products == The clearest commercial example is the SERI Surgical Scaffold, a knitted mesh of highly purified silk fibroin that originated in research at Tufts University and was first marketed by Serica Technologies. The U.S. Food and Drug Administration cleared it in 2009 as a temporary scaffold for the support and reinforcement of soft tissue; the product was subsequently held by Allergan and then by Sofregen Medical. After implantation the mesh provides immediate mechanical support and is gradually resorbed and replaced by the patient's own collagen. Silk sutures remain in widespread clinical use, and other silk-based products and devices are in development or early clinical testing.
The original parlor (a remodeled grocery store) at 57th and J Streets in Sacramento remained in business until the mid-1990s. The second Shakey's Pizza Parlor opened in Portland, Oregon, in 1956. Shakey's opened their third parlor in Albany, Oregon, in 1959, which was the first building Shakey's actually owned and the first building to be built in the distinct building style for which Shakey's is known. It now operates as a used bookstore. According to Johnson, Shakey's Pizza engaged in little market research and made most of its decisions on where to locate stores by going where Kinney Shoes opened stores. By the time Johnson sold his interest in 1967, there were 272 Shakey's Pizza Parlors in the United States. The first international store opened in Winnipeg, Manitoba, Canada, in 1968. By 1975, the company had expanded to the Pacific Rim, including Japan (in 1973) and the Philippines (in 1975). By the early 1970s, Shakey's had become popular with families and youth sports groups in Southern California. The long rows of picnic tables end-on-end facilitated large groups. Youth sports teams would go to Shakey's after their weekend games, where the kids could eat pizza and have fun, and the parents could drink beer and socialize. In fact, the advertising motto for Shakey's was "We serve fun at Shakey's... also pizza". One of the features of Shakey's was its large windows between the dining hall and the kitchen. One could order pizza and then watch as the dough was prepared, sauce and toppings added, and then pizza slid into the oven.
Sources: en.wikipedia.org
Aminopeptidase regulator of tumour necrosis factor receptor 1 (TNFR1) shedding (ARTS-1) Adipocyte-derived leucine aminopeptidase (A-LAP) Puromycin-insensitive leucyl-specific aminopeptidase (PILS-AP) KIAA0525 In mice, ER aminopeptidase associated with antigen processing (ERAAP)
Concurrent with the work of Rutherford, Geiger, and Marsden, the radiochemist Frederick Soddy at the University of Glasgow was studying chemistry-related problems on radioactive materials. Soddy had worked with Rutherford on radioactivity at McGill University. By 1910, about 40 different radioactive elements, referred to as radioelements, had been identified between uranium and lead, although the periodic table only allowed for 11 elements. Every attempt to chemically isolate the radioelements mesothorium or thorium X from radium failed. Soddy concluded that these element were chemically the same element. At the suggestion of Margaret Todd, Soddy called these chemically identical elements isotopes. In 1913, Soddy and theorist Kazimierz Fajans independently found the displacement law, that an element undergoing alpha decay will produce an element two places to the left in the periodic system and an element undergoing beta decay will produce an element one place to the right in the periodic system. For his study of radioactivity and the discovery of isotopes, Soddy was awarded the 1921 Nobel Prize in Chemistry.
In Greek legend there was a fighter named Antaeus who drew strength from the earth even when he was flung down. It took Hercules to work out his vulnerability as a wrestler. Hezbollah loves death, thrives on defeat and disaster, and is rapidly moving from being a state within a state to becoming the master of what was once the most cosmopolitan and democratic country in the Middle East. Meanwhile, a former superpower – no Hercules – is permitting itself to be made a hostage and laughing-stock by a squalid factional fight within the Israeli right wing involving the time and scale of petty land theft by zealots and fanatics. Only a few years from now, this, too, will seem hard to believe, as well as shameful and unpardonable.
Merit Award from the National Institute of Health American Society for Bone and Mineral Research Fuller Albright Award Mead Johnson Award Osborne and Mendel Award, the McCollum Award Robert H. Herman Award from the American Society for Clinical Nutrition ACN Award from the American College of Nutrition NIH’s General Clinical Research Center's Program Award for Excellence in Clinical Research Psoriasis Research Achievement Award from the American Skin Association DSM Innovation in Nutrition Award Van Slyke Award from American Association for Clinical Chemistry Linus Pauling Prize In Human Nutrition Delbert A Fisher Research Scholar Award from the Endocrine Society American College of Nutrition's Communication Media Award Institute of Functional Medicine’s LPI Award 2007
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.